WHAT IS THE COLLABORATION BETWEEN THE WEIZMANN INSTITUTE AND DEERFIELD MANAGEMENT COMPANY?
Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science, is collaborating with Deerfield Management Company, an investment firm dedicated to advancing healthcare. This collaboration aims to accelerate the translation of research in faculty laboratories towards clinical validation. Orchard Innovations is a private company wholly owned by Deerfield affiliates that will support The Weizmann Institute’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Orchard Innovations will fund projects with the aim of discovering novel therapeutics spanning a range of areas in medicine, including difficult-to-treat and rare illnesses. Through Orchard Innovations, Deerfield has committed up to $130 million in initial funding to support promising The Weizmann Institute translational research. Deerfield will additionally provide its operational, managerial and developmental know-how to further cutting-edge drug research spanning a range of areas in medicine, including difficult-to-treat and rare illnesses.
WHO IS ELIGIBLE TO APPLY?
Principal Investigators whose principal employer is The Weizmann Institute or who have a faculty appointment at The Weizmann Institute and are therefore subject to institutional policies are eligible to apply.
DOES ORCHARD INNOVATIONS HAVE A THERAPEUTIC AREA OF INTEREST?
No – We welcome applications from all therapeutic areas.